Literature DB >> 25271098

Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions.

Matthew J Page1, Joanne E McKenzie, Jamie Kirkham, Kerry Dwan, Sharon Kramer, Sally Green, Andrew Forbes.   

Abstract

BACKGROUND: Systematic reviews may be compromised by selective inclusion and reporting of outcomes and analyses. Selective inclusion occurs when there are multiple effect estimates in a trial report that could be included in a particular meta-analysis (e.g. from multiple measurement scales and time points) and the choice of effect estimate to include in the meta-analysis is based on the results (e.g. statistical significance, magnitude or direction of effect). Selective reporting occurs when the reporting of a subset of outcomes and analyses in the systematic review is based on the results (e.g. a protocol-defined outcome is omitted from the published systematic review).
OBJECTIVES: To summarise the characteristics and synthesise the results of empirical studies that have investigated the prevalence of selective inclusion or reporting in systematic reviews of randomised controlled trials (RCTs), investigated the factors (e.g. statistical significance or direction of effect) associated with the prevalence and quantified the bias. SEARCH
METHODS: We searched the Cochrane Methodology Register (to July 2012), Ovid MEDLINE, Ovid EMBASE, Ovid PsycINFO and ISI Web of Science (each up to May 2013), and the US Agency for Healthcare Research and Quality (AHRQ) Effective Healthcare Program's Scientific Resource Center (SRC) Methods Library (to June 2013). We also searched the abstract books of the 2011 and 2012 Cochrane Colloquia and the article alerts for methodological work in research synthesis published from 2009 to 2011 and compiled in Research Synthesis Methods. SELECTION CRITERIA: We included both published and unpublished empirical studies that investigated the prevalence and factors associated with selective inclusion or reporting, or both, in systematic reviews of RCTs of healthcare interventions. We included empirical studies assessing any type of selective inclusion or reporting, such as investigations of how frequently RCT outcome data is selectively included in systematic reviews based on the results, outcomes and analyses are discrepant between protocol and published review or non-significant outcomes are partially reported in the full text or summary within systematic reviews. DATA COLLECTION AND ANALYSIS: Two review authors independently selected empirical studies for inclusion, extracted the data and performed a risk of bias assessment. A third review author resolved any disagreements about inclusion or exclusion of empirical studies, data extraction and risk of bias. We contacted authors of included studies for additional unpublished data. Primary outcomes included overall prevalence of selective inclusion or reporting, association between selective inclusion or reporting and the statistical significance of the effect estimate, and association between selective inclusion or reporting and the direction of the effect estimate. We combined prevalence estimates and risk ratios (RRs) using a random-effects meta-analysis model. MAIN
RESULTS: Seven studies met the inclusion criteria. No studies had investigated selective inclusion of results in systematic reviews, or discrepancies in outcomes and analyses between systematic review registry entries and published systematic reviews. Based on a meta-analysis of four studies (including 485 Cochrane Reviews), 38% (95% confidence interval (CI) 23% to 54%) of systematic reviews added, omitted, upgraded or downgraded at least one outcome between the protocol and published systematic review. The association between statistical significance and discrepant outcome reporting between protocol and published systematic review was uncertain. The meta-analytic estimate suggested an increased risk of adding or upgrading (i.e. changing a secondary outcome to primary) when the outcome was statistically significant, although the 95% CI included no association and a decreased risk as plausible estimates (RR 1.43, 95% CI 0.71 to 2.85; two studies, n = 552 meta-analyses). Also, the meta-analytic estimate suggested an increased risk of downgrading (i.e. changing a primary outcome to secondary) when the outcome was statistically significant, although the 95% CI included no association and a decreased risk as plausible estimates (RR 1.26, 95% CI 0.60 to 2.62; two studies, n = 484 meta-analyses). None of the included studies had investigated whether the association between statistical significance and adding, upgrading or downgrading of outcomes was modified by the type of comparison, direction of effect or type of outcome; or whether there is an association between direction of the effect estimate and discrepant outcome reporting.Several secondary outcomes were reported in the included studies. Two studies found that reasons for discrepant outcome reporting were infrequently reported in published systematic reviews (6% in one study and 22% in the other). One study (including 62 Cochrane Reviews) found that 32% (95% CI 21% to 45%) of systematic reviews did not report all primary outcomes in the abstract. Another study (including 64 Cochrane and 118 non-Cochrane reviews) found that statistically significant primary outcomes were more likely to be completely reported in the systematic review abstract than non-significant primary outcomes (RR 2.66, 95% CI 1.81 to 3.90). None of the studies included systematic reviews published after 2009 when reporting standards for systematic reviews (Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement, and Methodological Expectations of Cochrane Intervention Reviews (MECIR)) were disseminated, so the results might not be generalisable to more recent systematic reviews. AUTHORS'
CONCLUSIONS: Discrepant outcome reporting between the protocol and published systematic review is fairly common, although the association between statistical significance and discrepant outcome reporting is uncertain. Complete reporting of outcomes in systematic review abstracts is associated with statistical significance of the results for those outcomes. Systematic review outcomes and analysis plans should be specified prior to seeing the results of included studies to minimise post-hoc decisions that may be based on the observed results. Modifications that occur once the review has commenced, along with their justification, should be clearly reported. Effect estimates and CIs should be reported for all systematic review outcomes regardless of the results. The lack of research on selective inclusion of results in systematic reviews needs to be addressed and studies that avoid the methodological weaknesses of existing research are also needed.

Entities:  

Mesh:

Year:  2014        PMID: 25271098      PMCID: PMC8191366          DOI: 10.1002/14651858.MR000035.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  86 in total

1.  Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research.

Authors:  An-Wen Chan; Karmela Krleza-Jerić; Isabelle Schmid; Douglas G Altman
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

2.  An international registry of systematic-review protocols.

Authors:  Alison Booth; Mike Clarke; Davina Ghersi; David Moher; Mark Petticrew; Lesley Stewart
Journal:  Lancet       Date:  2010-07-12       Impact factor: 79.321

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

4.  Outcome reporting in industry-sponsored trials of gabapentin for off-label use.

Authors:  S Swaroop Vedula; Lisa Bero; Roberta W Scherer; Kay Dickersin
Journal:  N Engl J Med       Date:  2009-11-12       Impact factor: 91.245

Review 5.  Review article: critical review of meta-analyses of randomized clinical trials in hepatogastroenterology.

Authors:  A Auperin; J P Pignon; T Poynard
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

6.  Article alerts: Introduction and items from 2009, part I.

Authors:  Adam R Hafdahl
Journal:  Res Synth Methods       Date:  2010-01       Impact factor: 5.273

Review 7.  Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study.

Authors:  Bruno R da Costa; Eveline Nüesch; Anne W Rutjes; Bradley C Johnston; Stephan Reichenbach; Sven Trelle; Gordon H Guyatt; Peter Jüni
Journal:  J Clin Epidemiol       Date:  2013-06-06       Impact factor: 6.437

8.  Bias due to changes in specified outcomes during the systematic review process.

Authors:  Jamie J Kirkham; Doug G Altman; Paula R Williamson
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study.

Authors:  Britta Tendal; Eveline Nüesch; Julian P T Higgins; Peter Jüni; Peter C Gøtzsche
Journal:  BMJ       Date:  2011-08-30

10.  PROSPERO at one year: an evaluation of its utility.

Authors:  Alison Booth; Mike Clarke; Gordon Dooley; Davina Ghersi; David Moher; Mark Petticrew; Lesley Stewart
Journal:  Syst Rev       Date:  2013-01-15
View more
  80 in total

1.  Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

Authors:  Sonam Vadera; Charles Wei Kit Yong; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-20

Review 2.  Treatment of drug-resistant fibromyalgia symptoms using high-intensity laser therapy: a case-based review.

Authors:  Paul F White; Jason Zafereo; Ofelia Loani Elvir-Lazo; Hector Hernandez
Journal:  Rheumatol Int       Date:  2017-10-28       Impact factor: 2.631

Review 3.  The COMET Handbook: version 1.0.

Authors:  Paula R Williamson; Douglas G Altman; Heather Bagley; Karen L Barnes; Jane M Blazeby; Sara T Brookes; Mike Clarke; Elizabeth Gargon; Sarah Gorst; Nicola Harman; Jamie J Kirkham; Angus McNair; Cecilia A C Prinsen; Jochen Schmitt; Caroline B Terwee; Bridget Young
Journal:  Trials       Date:  2017-06-20       Impact factor: 2.279

Review 4.  A systematic review of the outcomes reported in trials of medication review in older patients: the need for a core outcome set.

Authors:  Jean-Baptiste Beuscart; Lisa G Pont; Stefanie Thevelin; Benoit Boland; Olivia Dalleur; Anne W S Rutjes; Johanna I Westbrook; Anne Spinewine
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

5.  Post-randomization bias.

Authors:  Chad Cook; Alessandra N Garcia
Journal:  J Man Manip Ther       Date:  2020-05

6.  Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Authors:  Harry D Zacharias; Antony P Zacharias; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

7.  Reporting bias in imaging: higher accuracy is linked to faster publication.

Authors:  A Dehmoobad Sharifabadi; D A Korevaar; T A McGrath; N van Es; R A Frank; L Cherpak; W Dang; J P Salameh; F Nguyen; C Stanley; M D F McInnes
Journal:  Eur Radiol       Date:  2018-03-21       Impact factor: 5.315

Review 8.  A low proportion of systematic reviews in physical therapy are registered: a survey of 150 published systematic reviews.

Authors:  Crystian B Oliveira; Mark R Elkins; Ítalo Ribeiro Lemes; Danilo de Oliveira Silva; Ronaldo V Briani; Henrique Luiz Monteiro; Fábio Mícolis de Azevedo; Rafael Zambelli Pinto
Journal:  Braz J Phys Ther       Date:  2017-10-26       Impact factor: 3.377

9.  Interventions to reduce morbidity from vault hematoma following vaginal hysterectomy: a systematic review and meta-analysis.

Authors:  Suneetha Rachaneni; Anupreet Dua
Journal:  Int Urogynecol J       Date:  2018-11-29       Impact factor: 2.894

Review 10.  Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Lise Lotte Gluud; Hendrik Vilstrup; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2016-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.